LGND
LIGAND PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jan 5 to Jan 15 ▲ 2 buys: Gilbert Cisneros bought $1,001 - $15,000, last disclosed Feb 16
- Mar 3 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Apr 8
- Apr 14 ▲ Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsent…
- May 29 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Jun 9
- Aug 12 ▼ 2 insiders sell $11.3M at $292.20
- Sep 3 to Sep 10 ▼ 2 days of insider sells: $1.8M by 2 insiders, avg $285.88
- Sep 25 Barclays initiates
- Oct 2 ▼ 1 insider sell $1.5M at $304.07
- Oct 29 ▲ Earnings: LGND Q3 2026 Earnings: EPS $2.67 (+9.9% vs est)
- Oct 29 ▲ Ligand Pharmaceuticals reported Q3 2026 royalty revenue of $70.3M, u…
- Oct 29 ▲ Ligand Pharmaceuticals reported Q3 2026 adjusted EPS of $2.67, beati…
- Oct 30 to Nov 10 ▼ 4 days of insider sells: $3.3M by 2 insiders, avg $316.81
- Nov 12 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersMIXED
5 insiders sold $17.9M. Excludes 1 subscriber-only trade.
- InstitutionsBULLISH
Q3 2026: 28 added (2 new), 14 trimmed or exited. Largest new: William Blair Investment Management $37.3M, Hrt Financial $27.9M.
- AnalystsBULLISH
16 of 17 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −1.5% to 2.46M shares. 10.5 days to cover, ≈12.3% of shares.
- TrendUPTREND
2% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Invesco Ltd. | ADD | $469.7M |
| Neuberger Berman Group LLC | ADD | $112.0M |
| UBS Group AG | ADD | $53.5M |
| Russell Investments Group, Ltd. | ADD | $53.1M |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | $47.4M |
| CITIGROUP INC | ADD | $40.6M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $39.9M |
| PRINCIPAL FINANCIAL GROUP INC | ADD | $39.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +13%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Barclays MAINTAIN | Overweight |
| Nov 5, 2026 | Citigroup MAINTAIN | Buy |
| Oct 30, 2026 | RBC Capital MAINTAIN | Outperform |
| Sep 25, 2026 | Barclays INITIATE | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 23, 2026 | Citigroup MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 12, 2026 | SELL | |
Aryeh Jason Director Nov 10, 2026 | SELL | $160.1K |
Aryeh Jason Director Nov 10, 2026 | SELL | $160.0K |
Aryeh Jason Director Nov 10, 2026 | SELL | $270.1K |
Aryeh Jason Director Nov 10, 2026 | SELL | $206.7K |
Aryeh Jason Director Nov 10, 2026 | SELL | $3.2K |
Aryeh Jason Director Nov 10, 2026 | SELL | $160.1K |
Aryeh Jason Director Nov 4, 2026 | SELL | $90.2K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $2.36 | $2.31–$2.41 | +2.5% | $76.1M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
28 filings · 1 press release · 4 bullish · 0 bearish · 2 mixed · 22 neutral- NEUTRAL CLUSTERNov 16, 2026
Two directors sold a total of $796K in open-market sales over a 7-day window, with no 10b5-1 plans in place. The sales represent about 0.013% of market cap, well below the materiality threshold, and are not accompanied by any adverse corporate filing or event.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Janus Henderson Group Ltd. filed an amended Schedule 13G disclosing a 4.6% passive stake in Ligand Pharmaceuticals as of September 30, 2026, down from a prior filing's 7.6% stake by Invesco Ltd. The filing reflects a routine passive portfolio adjustment by a new filer, with no indication of…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 12, 2026
Director Martine Zimmermann filed a Form 144 notice of intent to sell 2,000 shares of Ligand…
This is a routine director sale of shares acquired through equity compensation. The small size relative to market cap suggests no material insider concern. Monitor for any subsequent Form 4 filings…
- NEUTRAL 144Nov 12, 2026
Director John W. Kozarich filed a Form 144 notice of intent to sell 500 shares of Ligand…
The sale amount is immaterial relative to the company's market cap and typical director holdings. No further action warranted unless a pattern of larger insider sales emerges.
All LGND filing & press-release reports (29)
- CLUSTER reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- 144 reportNov 12, 2026
- 144 reportNov 12, 2026
- 144 reportNov 12, 2026
- SC 13G/A reportNov 10, 2026
- 144 reportNov 10, 2026
- CLUSTER reportNov 6, 2026
- 144 reportNov 4, 2026
- CLUSTER reportNov 4, 2026
- 144 reportNov 2, 2026
- 144 reportOct 30, 2026
- 144 reportOct 30, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- INST-CLUSTER reportOct 27, 2026
- PRESS-RELEASE reportOct 15, 2026
- 8-K reportSep 24, 2026
- 8-K reportSep 22, 2026
- CLUSTER reportSep 14, 2026
- CLUSTER reportAug 14, 2026
- 8-K reportAug 6, 2026
- 8-K reportJun 25, 2026
- CLUSTER reportJun 18, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 12, 2026
- CLUSTER reportMay 1, 2026
- PRESS-RELEASE reportApr 14, 2026
- 8-K reportFeb 26, 2026